La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
ShanXi C&Y Pharmaceutical GroupLTD Bilan de santé
Santé financière contrôle des critères 4/6
ShanXi C&Y Pharmaceutical GroupLTD has a total shareholder equity of CN¥803.4M and total debt of CN¥230.4M, which brings its debt-to-equity ratio to 28.7%. Its total assets and total liabilities are CN¥1.5B and CN¥672.9M respectively. ShanXi C&Y Pharmaceutical GroupLTD's EBIT is CN¥37.8M making its interest coverage ratio 1.7. It has cash and short-term investments of CN¥131.9M.
Informations clés
28.7%
Ratio d'endettement
CN¥230.38m
Dette
| Ratio de couverture des intérêts | 1.7x |
| Argent liquide | CN¥131.92m |
| Fonds propres | CN¥803.38m |
| Total du passif | CN¥672.86m |
| Total des actifs | CN¥1.48b |
Mises à jour récentes de la santé financière
Pas de mise à jour
Recent updates
ShanXi C&Y Pharmaceutical Group Co.,LTD.'s (SZSE:300254) 36% Price Boost Is Out Of Tune With Revenues
May 27
ShanXi C&Y Pharmaceutical Group (SZSE:300254) Strong Profits May Be Masking Some Underlying Issues
Mar 25ShanXi C&Y Pharmaceutical Group Co., Ltd.'s (SZSE:300254) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Mar 06Analyse de la situation financière
Passif à court terme: 300254's short term assets (CN¥417.3M) do not cover its short term liabilities (CN¥447.2M).
Passif à long terme: 300254's short term assets (CN¥417.3M) exceed its long term liabilities (CN¥225.6M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 300254's net debt to equity ratio (12.3%) is considered satisfactory.
Réduire la dette: 300254's debt to equity ratio has reduced from 29.4% to 28.7% over the past 5 years.
Couverture de la dette: 300254's debt is well covered by operating cash flow (34.7%).
Couverture des intérêts: 300254's interest payments on its debt are not well covered by EBIT (1.7x coverage).